GlassScriptPhysician profile
Barry O Baker
NPI 1497716690
$1,263.26
in general payments reported to CMS, 2019-2025
26 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $179 · 2022: $159 · 2023: $110 · 2024: $388 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $278.58 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $206.78 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $131.27 | 2021-2025 | |
| Amgen INC. | $80.48 | 2022-2024 | Evenity, Prolia |
| Pfizer INC. | $75.66 | 2022-2025 | |
| Corium, LLC | $50.24 | 2024 | Azstarys |
| Glaxosmithkline, LLC. | $48.41 | 2021-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $42.40 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $33.92 | 2024 | Spravato |
| Merck Sharp & Dohme LLC | $33.16 | 2025 | Rotateq, Vaxneuvance, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.98 | 2021-2025 | |
| Seqirus USA INC | $21.76 | 2024 | Fluad, Flucelvax |
| Mylan Specialty L.P. | $21.38 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $18.69 | 2025 | |
| Vbi Vaccine (Delaware) INC. | $18.14 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.81 | 2024 | Veozah |
| Sage Therapeutics, LLC | $17.18 | 2022 | |
| Novo Nordisk INC | $16.83 | 2021 | |
| Kyowa Kirin, INC. | $16.59 | 2023 | Crysvita |
| E.R. Squibb & Sons, L.L.C. | $16.38 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.61 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $15.18 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.72 | 2021 | |
| Medtronic, INC. | $14.03 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.58 | 2024 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.